November 17 & 18, 2020
The two day summit will convene hundreds of international drug developers and researchers to share their cutting edge ideas, lessons learned and findings.
Forge lasting collaborations, present emerging science, and explore new tools & technologies that will transform your science and accelerate your work.
During the Summit you can take virtual walk around the venue in a 3D world, listen to our global speakers, and ask questions during our poster sessions from your peers and visit solutions exhibition stands, and don’t forget to use your time to network with other participants.
In the nearly two decades since the human genome was first sequenced, there has been an explosion of insights into the role of genetics in a vast array of diseases. Genetic medicines are a promising new class of medicine that was not possible even a short time ago.
Join us and let's kick-off this revolution together.
Dr. Pieter Cullis, Scientific Director & CEO, NanoMedicines Innovation Network, Canada’s National Centre of Excellence in Nanomedicines, whose work has contributed to three LNP products that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications
Dr. Jeffery B. Ulmer, with over 30 years experience in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis Vaccines and GSK
Dr. Michael Houghton, winner of the Nobel Prize in Physiology or Medicine 2020 for his crucial role in identifying the virus that causes hepatitis C
Dr. Norbert Pardi, Assistant Professor from the Perelman School of Medicine at the University of Pennsylvania and has been working on the development of universal influenza vaccines using his mRNA-based vaccine platform
Dr. Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Medicine at Imperial College London, where his research has led to the establishment of international collaborations aimed at preclinical identification, development and selection of HIV microbicide and vaccine candidates prior to formal clinical efficacy trials
Dr. Sharon Wang, Vice President of Technical Development at Ultragenyx where she leads process development function for Ultragenyx products including messenger RNA, therapeutic proteins, antibodies, oligonucleotides and small molecules
Dr. Kurt Kamrud, Director of the Genomic Platforms Group within Science and Innovation Direction at Ceva Animal Health with over 25 years of experience in molecular virology
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.